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Abstract
Background: The incidence of head and neck cancer is increasing slightly. Head and neck cancer but also it’s
necessary and often successful treatment may affect general domains of health-related quality of life and provoke a
variety of adverse symptoms and side effects, both during and after treatment. The objective of this study was to
compare a person-centred care intervention in terms of health-related quality of life, disease-specific symptoms or
problems, with traditional care as a control group for patients with head and neck cancer.
Methods: In this randomized controlled trial, person–centred-care intervention and traditional care (control) groups
comprised 54 and 42 patients, respectively. Outcome measures used were: the EORTC QLQ-C30 and the EORTC
QLQ-C35. Both groups answered the questionnaires at baseline and after 4, 10, 18 and 52 weeks from start of
treatment. The questionnaires’ scores were compared between groups by using independent samples test and
non-parametric test for continuous variables. For categorical data, Fisher’s exact test was used. Longitudinal data
were analysed using generalized linear models for normally distributed repeated measures data.
Results: At baseline, the intervention and control groups were comparable in terms of medical and sociodemographic
variables, clinical characteristics, health-related quality of life and disease-specific symptoms or problems. At all the
follow-up points, even during the worst period for the patients, the person-centred-care group consistently reported
better scores than the control group. The differences were numerically but not always statistically significant. When
testing longitudinal data, statistically significant results were found for head and neck cancer-specific problems,
swallowing (p = 0.014), social eating (p = 0.048) and feeling ill (p = 0.021).
Conclusions: The results from this study suggest that adopting the person-centred-care concept practiced here could
be a way to improve function and wellbeing in patients with head and neck cancer.
Trial registration: The study was retrospectively registered in 2016-12-05 in Clinical Trials gov. “Can a Person-centred-
care Intervention Improve Health-related Quality of Life in Patients With Head and Neck Cancer” registration number:
NCT02982746.
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Background
Annually, approximately 1400 new cases of head and
neck cancer (HNC) are diagnosed in Sweden. The inci-
dence of HNC is increasing slightly, especially for oro-
pharyngeal carcinoma due to human papilloma virus
(HPV). Long-term survival varies with the sub site, but
the disease-specific survival rate in general is approxi-
mately 60%. The tumours often affect vital functions
causing eating, breathing and communication symptoms.
They also influence speech, sight and hearing abilities, as
well as body image and appearance [1]. HNC but also
it’s necessary and often successful treatment may affect
general domains of health-related quality of life (HRQoL)
and provoke a variety of adverse symptoms and side
effects, both during and after treatment. Symptoms such
as severe mucosal reactions, nausea, dysphagia xerostomia
and taste changes cause nutritional problems and persist
usually throughout the treatment regime and then grad-
ually improve during the first year after treatment [2–4].
Other frequently experienced symptoms and side effects
such as pain, vomiting and fatigue during extended
periods are all problems that are lowering quality of life
contributing to social negative effects like prolonged work
ability and in the long run also the survival [5–7]. Due to
the tumour’s localization, the symptoms usually lead
to eating difficulties and the patients usually need
enteral feeding via a PEG (Percutaneous Endoscopic
Gastrostomy) or NG (Nasogastric tube).
Patients affected by HNC have traditionally been
described as a vulnerable group with a poor prognosis,
and the diagnosis is often associated with tobacco and
alcohol abuse. The disease usually affects older men
(median age 66 years) and, to some extent, individuals
from a lower socio-economic background. The increase
in the incidence of oropharyngeal cancer has been linked
to HPV infection [8]. Notably, patients with HPV-
positive oropharyngeal cancer are younger than the aver-
age age of people affected by HNC (median age 62 years)
and are most often non-smokers [9, 10]. Earlier studies
have shown that patients with HNC experience deterior-
ation in HRQoL during and up to a year after treatment
[2, 11]. The rates of depression related to the physical
symptoms have also been found to increase among
patients suffering from HNC [12–14]. The suicide rates
for people affected by HNS are substantially higher than
in both the general population and the overall popula-
tion of patients with cancer [15].
The national health-care system serving patients
suffering from such complex and multifaceted diseases
as HNC has been characterized by an insufficient co-
ordination and continuity of care and treatment [16]. In
the case of patients with HNC in Sweden, there are too
few outpatient clinics and the primary-care centres are
not able to treat these patients sufficiently well. This is a
well-known scenario for certain types of diagnoses
resulting in a lack of continuity in the transition of pa-
tients between hospital and primary care [16–19]. Today
there is nobody among the professionals who coordi-
nates the care. In teams focusing on person-centred care
(PCC), the patients are seen as partners and therefore as
a member of the team [20]. The rationale for this is that
knowledge of the patient’s everyday life, abilities and
perceptions is regarded as the key to planning care in
partnership with the patient [21]. Patients are expected
to be actively involved in both the planning and execu-
tion of the care and rehabilitation process. A PCC
philosophy defined as Gothenburg person-centred care
(gPCC) emphasizes that the patient’s own resources can
make the difference between a successful and a less suc-
cessful rehabilitation process [21]. gPCC teams have
been shown to be capable of successfully combining
high-quality health care and focusing on the patient’s
own goals [21–23].
Consequently, there is a need to evaluate whether a
person-centred team intervention can improve symptom
control with preserved function and quality of life.
The aim of this study was to compare a person-
centred care intervention in terms of HRQoL related to
disease-specific symptoms or problems, with traditional
care as a control group for patients with HNC.
Methods
Study design
We conducted a single-centre, randomized, longitudinal
controlled study with an intervention group (gPPC-G)
and a control group (CG). The study was performed
between the spring of 2012 and the spring of 2014 at
Sahlgrenska University Hospital in Sweden.
Participants
The incidence of HNC in the hospital’s catchment area
is around 260 patients per year, approximately 20% of
the incidence in the entire country. Eligible for this study
were patients diagnosed with HNC, older than 18 years
and able to read and write Swedish. The patients should
be suitable for outpatient treatment with chemo- and/or
radiotherapy, either as primary treatment or in a postop-
erative setting, decided of an oncologist. Patients were
excluded if they had a previous or concomitant malig-
nancy or were diagnosed and treated for depression as
stated in their medical record. To avoid influences from
other studies, none of the patients were to be included if
they were taking part in other research studies.
Power analysis and randomisation
Power calculation was performed based on the EORTC
QLQ-30 instrument and it showed that around 100
patients were needed to achieve 80% power to detect a
Hansson et al. BMC Nursing  (2017) 16:9 Page 2 of 12
20% difference at the 5% significance level (mean value
of 63 and SD 23,9 for General Quality Of life, EORTC
QLQ30 instrument) [24].
A total of 101 patients were identified as eligible for
inclusion (Fig. 1). The study was explained and patients
were asked by the oncologist to participate. Five patients
declined to participate. Both written and verbal informed
consent was thus obtained from 96 consecutively
selected patient diagnosed with HNC classified in stages
I–IV, they were randomized to either the gPCC-G or the
CG (Fig. 1). The randomization of the patients took
place at the outpatient clinic in connection with the first
meeting with the oncologist. Because this particular type
of intervention had never been attempted with this
patient group, and since we did not expect any negative
effects of the intervention, we assumed that the inter-
vention group needed to be larger than the control
group. Randomization was conducted and handled by
the study nurse, as a computerized randomization
process and using sealed opaque envelopes, assigning
60% of the patients to the intervention group (n = 54)
and 40% to the control group (n = 42) (Fig. 1). Due to
practical reasons no one was blinded after randomisation.
Treatment procedure
With a few exceptions, all of the patients being treated
at the hospital are routinely discussed and assessed at a
weekly multidisciplinary tumour board. Thereafter, the
physician discusses the treatment options with the
patients and their relatives and, for the few patients not
Fig. 1 CONSORT DIAGRAM, flow chart of the participants in the gPCC—G and the CG
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participating in the multidisciplinary treatment conference,
this discussion is held at a scheduled meeting with the on-
cologist. The treatment, which includes chemotherapy and
radiotherapy according to the chosen treatment strategy,
usually starts within 2 weeks. During the treatment period,
which often lasts up to 6 weeks, the patients are seen at
weekly consultations with a physician at the radiotherapy
department. After the treatment, normally after a period
of 6 to 8 weeks, the follow-up routines include an initial
return visit, followed by a visit every 3 months for 2 years,
preceded by a radiological evaluation. After discharge from
the clinic, the patients are referred back to their local
hospitals or their primary-care centres for support in the
event of any complications that might arise. No follow-up
appointments with nurses are usually made, but the
patients are given a phone number they can call if needed.
Control group (CG)
Patients randomized to the control group received usual
care and return visits were scheduled according to the
treatment procedure described under the previous heading
and based on the Regional care program for patients with
HNC [25]. CG patients were recruited at the same time
and in the same way as those in the intervention group.
The gPCC intervention group (gPCC-G)
Patients randomized to the intervention group were
contacted and scheduled to attend a meeting at the
oncology clinic with the nurse specialist in oncology,
accompanied by a close relative, if possible, within 7 days
after their first visit to the oncologist. This first meeting
included a description of the study as well as informa-
tion needed about the health-care plan. The plan was
designed and developed according to a basic model from
gPCC and further adapted to suit patients with HNC
and scheduled by the nurse and patient together. Fur-
thermore, the nurse informed the patients and relatives,
orally and in writing, about symptoms and side-effects
known to have an impact on quality of life, such fatigue,
nutrition problems, weight loss, pain and nausea. The
patients were asked to describe their life situation (work,
leisure time, stress, family and social life, social support
and potential problems), experiences regarding diagnosis
and treatment, and prior experience relating to nausea
and pain. As needed, other factors associated with life-
style (diet, smoking, alcohol consumption, mental health
etc.) were discussed. The patient and the nurse shared
information by reviewing the medical record relating to
previous blood tests, X-ray examinations, chemotherapy,
radiotherapy, use of medications and the validation of
symptoms such as pain and fatigue. Each patient also de-
scribed her/his eating problems and treatment strategies
were advised and discussed. In this partnership, factors
in the patient’s narrative which were considered crucial
for addressing eating problems, such as weight loss,
nausea and pain, were identified, clarified and concret-
ized. Patient involvement in planning was emphasized.
The treatment process was discussed to suit each
person’s circumstances as a part of the health-care plan.
The patient’s preferences, goals and indications for and
barriers to the impending treatment, including personal,
environmental and social factors, were discussed. An im-
portant factor taken into account was to ensure that
symptoms and side effects of treatment would not com-
promise the perceived balance between life activities.
The health-care plan comprised self-management goals
that were formed in partnership between the patient and
the nurse. Each patient was encouraged to reflect on
their self-management goals, how to reach them, and to
anticipate barriers; and to refine the plan. The health
plan includes both short- and long-term goals for the
patient along with the actions needed to reach each goal.
The plan is a “living” document specific to each patient,
in which the goals and actions are tracked and revised
over time. Because the treatment greatly affects the
patient’s quality of life and ability to eat, the plan
encourages constant discussion about whether the
patient is managing these symptoms and side effects, or
whether an NG or PEG is needed or whether
hospitalization is necessary. The patient was also given a
direct telephone number to reach the nurse specialist if
they had any questions about anything relating to their
treatment and wellbeing. The nurse documented the
health-care plan in the medical record.
Data collection and measurement
The patients answered the first set of questionnaires
either in the hospital after the multidisciplinary treat-
ment conference or at home. The remaining sets of
questionnaires were answered at 4, 10, 18 and 52 weeks
after the start of treatment. The oncologists’ clinical
knowledge was that the time points chosen typically rep-
resented significant but different clinical symptom stages
during of the treatment. The questionnaires were
returned by the patients by post, in a prepaid envelope.
The survey consisted of two outcome measurements:
the European Organization for Research and Treatment
of Cancer (EORTC) QLQ-C30 and the EORTC QLQ-35
version 3.0.
The EORTC QLQ-C30 is a cancer-specific instrument
that has been developed for measuring HRQoL in clin-
ical trials and is widely used. It has a good psychometric
property for use with patients affected by HNC. The
questionnaire consists of five sub-scales; physical function,
role function, emotional function, cognitive function and
social function, three symptom scales (nausea, pain and
fatigue), global health status (GHS), and six single-
symptom items, making a total of 30 questions. All scores
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result in a value between 0 and 100; high scores on func-
tional and global quality of life imply a high level of func-
tion, while a higher score on the symptom scales indicate
greater problems [3, 24, 26–28]. In the present study, we
have focused on the five subscales, one symptom scale
(pain) and the GHS.
The EORTC QLQ-35 is a cancer-specific instrument
developed to measure common symptoms related to
patients with HNC. The instrument comprises 35 ques-
tions, seven multiple-item scales that assess the symp-
toms of pain, swallowing ability, senses (taste/smell),
speech, social eating, social contact, sexuality and six
single-item scales, which survey the presence of symp-
tomatic problems associated with teeth, mouth-opening,
dry mouth (xerostomia), sticky saliva, coughing, and
feeling ill. All scales and single items are scored from 0
to 100; a high score corresponds with a high level of
symptoms or problems. A Swedish version of the instru-
ment appears to be reliable, valid and applicable to
broad multicultural samples of patients with HNC [29].
In the current study we have replaced the questions
about feeding tube, nutritional support and weight loss
with those related to similar issues but framed within
the study context: “Weight loss changes in percent from
baseline to study completion”, “feeding tube or PEG dur-
ing the treatment period” and “used nutritional support
during the treatment period”.
The EORTC QLQ-35, in conjunction with the EORTC
QLQ-30, can be regarded as a standard instrument to
measure HRQoL and diagnose specific symptoms in
patients with HNC [24, 30].
For all patients, their sociodemographic and medical
data were gathered and documented based on those
recorded in their medical record (Table 1).
Statistical Analysis
Analyses for this trial were completed on an intention-
to-treat basis and data from all the individuals who
entered the trial and answered the questionnaires were
analysed by initial group assignment. Demographic data
were expressed as number (n), percent (%), mean and
standard deviation (SD) and 95% confidence interval
(CI). The EORTC QLQ 30 and EORTC QLQ 35 scores
were compared between groups by using independent
samples test (Student’s t-test) and non-parametric test
(Mann-Whitney U Test) for continuous variables. For
categorical data, Fisher’s exact test was used.
The longitudinal data were analysed by using gen-
eralized linear models for normally distributed re-
peated measures data with treatment group, time and
interaction between treatment group, and time as
fixed effects and baseline value as covariate. The
generalized linear model used in all models was com-
pound symmetry.
Least Square Means with associated 95% CI are pre-
sented for both groups and for the difference between
the two groups and the corresponding p-value for the
difference.
All tests were two-tailed and conducted at 0.05 signifi-
cance level.
SPSS version 21 and SAS Software (version 9.4) were
used for statistical calculations.
Results
Data were obtained from 88 of the 96 persons treated
for HNC. Of the eight patients who did not complete all
the questionnaires, three were from the CG (withdrawn
after consent and disease progression < 4 weeks after the
start of the treatment). Five patients died during the
study; three from the gPCC-G (one patient between sec-
ond and third follow up and two patients between third
and fourth follow up) and two from the CG (one pa-
tients between baseline and the first follow up and one
Table 1 Baseline characteristics for the intervention group





Age Mean (at baseline) (SD) 61 (7.8) 62 (10.5)
Male (%) 70 69
Employed (yes) (%) 67 41




Neck node with unknown primary 6 5
Hypopharynx 6 0
Oral cavity 4 5
Parotid gland 4 0








Chemo radiotherapy 72 76
Primary radiation 28 24
HPV positive (%) 68 62
HPV negative (%) 13 26
HPV not known (%) 19 12
Values are mean, standard deviation (SD) and %
HPV Human papillomavirus
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patient between third and fourth follow up) (Fig. 1). The
internal response rate varied somewhat between the
measurement points, from 93% (gPCC-G) and 86% (CG)
at baseline, to 78% (gPCC-G) and 69% (CG) at 4 weeks,
82% (gPCC-G) and 71% (CG) at 10 weeks, 87% (gPCC-
G) and 67% (CG) at 18 weeks, and 85% (gPCC-G) and
69% (CG) at 52 weeks. No statistically significant dif-
ferences between the groups were found in this
respect—except at the 18-week measurement point,
when the response rate in the intervention group was
higher (p = 0.024).
All patients in the intervention group received person-
centred care; no one refused such treatment during the
study period.
At baseline, the gPCC-G and the CG were compar-
able in terms of sociodemographic variables, clinical
characteristics, HRQoL and disease-specific symptoms
(Table 1 and Figs. 2 and 3).
During the follow-up year the internal response rates
and pattern of change in the scores over time were strik-
ingly similar in both the groups (Figs. 2 and 3). Between
the 4th to 10th week measuring points, all the scales
were at their lowest or highest, indicating that this was
the time period during which the patients experienced
the worst HRQoL. After this deterioration, both groups
gradually improved to levels that, at least for the
gPCC-G, were better than at baseline (Figs. 2 and 3).
From 4 weeks on, the gPCC-G reported numerically
higher scores. When the sub-scales were tested with
a cross-sectional analysis (at each measurement
point), statistically significant differences between the
two groups were found for most of the sub-scales at
Fig. 2 Mean values and standard deviation (SD) of the Global Health status and Role Function (QLQ-30) sub-scores at the five the measurement
points, for both groups
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the 18th and/or 52nd week’s measurement points
(Figs. 2 and 3), both for HRQoL and HNC-specific
problems.
When the analysis was advanced by using generalized
linear models for normally distributed repeated mea-
sures data a similar pattern as that found in the
cross-sectional analysis was revealed, that is to say,
the results in the gPCC-G tended, from the 10th
week, to be better than those in the CG and were,
from the 18th week, statistically significantly better in
the gPCC-G in terms of HNC-specific problems
(QLQ-35), swallowing (p = 0.014), social eating (p = 0.048)
and feeling ill (p = 0.021) (Table 3). The gPCC-G reported
numerically higher scores but these were not significantly
better than those reported by the CG in terms of HRQoL
(QLQ-30) (Table 2).
Fig. 3 Mean values and standard deviation (SD) of the Swallowing, Social eating and Felt ill (QLQ-35) sub-scores at the five measurement points,
for both groups
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There were no differences found between the groups
at any of the follow-ups (cross-sectional analysis) for
specific problems such as senses of smell and taste,
teeth, opening mouth, dry mouth, sticky salvia and the
use of pain-killers (QLQ 35).
All patients in both the groups lost weight during the
follow-up year. The average loss was 9.8% for the gPCC-G
and 8.1% for the CG.
Almost 80% in both groups were supplied with a feeding
tube or a PEG at least once during the follow-up year.
Discussion
To survive their cancer, patients affected by HNC must
undergo a very challenging treatment regime. The associ-
ated side effects of this treatment, such as pain, difficulties
with food intake, loss of taste, dry mouth and risk of
weight loss, can lead to the patient’s whole existence be-
coming seriously and adversely affected. To support and
assist the patients during this treatment period, gPCC has
been tested and compared with traditional care.
The main result in this study is that the response pat-
tern and the progress during the follow-up year were
quite similar in both groups. However, at all of the
follow-up points the gPCC-G consistently reported bet-
ter scores than the CG. The differences were numerically
but not always statistically significant (Figs. 2 and 3 and
Tables 2 and 3). All of the scales, both from the QLQ-30
and the QLQ-35 noted the lowest or highest (worst)
value at the 4-week measurement point, indicating that
this was the time period during which the patients expe-
rienced as the worst HRQoL fairly consistently. Murphy
[12] reported a similar pattern, with a decline in HRQoL
immediately after the start of therapy and a return to-
ward baseline values after 1 year in patients with HNC.
After the consistent decline noted in both the groups in
the current study, the subsequent gradual improvement,
at least for the gPCC group, was higher than for the
baseline values (Figs. 2 and 3). A Cochrane review by
Semple [31] concluded that there was no evidence to
suggest that psychosocial intervention promotes global
quality of life for patients with HNC at the end of the
intervention. The only study we found with a compar-
able intervention was conducted by van der Meulen
[32], who had a reactive approach in their intervention,
with the emphasis on discussing problems and giving in-
formation and advice. In our study, we have a proactive
approach with a person-centred focus. The proactive
approach was based on the initial patient history and
partnership, which resulted in a health plan where the
patient’s individual needs were documented. Together
with continuity and accessibility, these were the key
components of the gPCC intervention and this created
safe, supportive care.
Our results are in agreement with the findings in an-
other study by van Der Meulen et al [33]. In their study,
a nurse-led intervention had beneficial effects on some
symptoms, for example pain and swallowing. In the
present study, symptoms such as swallowing, social eat-
ing and feeling ill were significantly better in the gPCC-
G, even when using repeated measures in covariance
pattern models. However, in the current study, we could
not see any statistical difference in terms of weight loss,
as all patients in both the gPCC- G and the CG lost
weight during the follow-up year. The average loss was
9.8% and 8.1%, respectively. One explanation could be
that tumor location, stage and performance status and
presence of dysphagia influenced the individual symp-
toms that predict impaired food intake. Almost 80% in
both the groups were supplied with a feeding tube at
least once during the follow-up year, and this did not
affect the participants’ perceptions of their general or
disease-related quality of life.
Van der Muelen [32] showed that a nurse-led psycho-
social intervention had a long-term effect on HRQoL,
particularly in terms of emotional and physical function-
ing, pain and depressive symptoms. The development of
all outcome measurements in the current study gener-
ally corresponded with what has been noted in earlier
longitudinal observational studies [24, 32, 34]. Although
not always statistically significantly different, the results
for the gPCC-G consistently tended to be better than
those in the CG. One plausible explanation for the posi-
tive effect of the gPCC intervention on HRQoL, noted
in earlier studies, could be the person-centred assess-
ment and the health plan developed by the nurses and
the patients together [23, 35]. The reason why the health
plan does have such an effect is probably because it is
developed based on the individual patient’s self and that
the health plan is subjected to continuous revision if
needed. The continuity with the specialised oncology
nurses which was an important part of the intervention
and the health plan probably also contributed. In a pre-
vious paper, we described how patients in both groups
showed a high degree of trust in the cancer clinic [16].
According to usual practice, if problems developed, the
patients in the control group were asked primarily to
contact the health-care centre. This frequently resulted
in a feeling of being abandoned after discharge, which,
to a great extent, explained the increasing distrust
shown by the control group, while the opposite was
noted in the intervention group [16].
The limitations of our study include the fact that a
number of patients did not respond to all of the ques-
tionnaires. The internal response rate was lowest at 4
and 10 weeks. It is possible that having a greater number
may have revealed differences not distinctly verified
here. However, when using the longitudinal data
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analysis, the missing data are handled. The study was
completed on an intention-to-treat basis. A per-protocol-
analysis would have needed a detailed information on how
well each patient had completed the care plan, informa-
tion not included in this study. All patients in the inter-
vention group received person-centred care; no one
refused such treatment during the study period, but as
could be expected in their own personal way.
The study took place at just one centre, but in-
cluded a large catchment area, which might restrict
the generalizability of the findings. Contamination or
dissemination of the intervention to the control group
which could be a risk for a one centre study was un-
likely since the patients were outpatients with small
chances to meet.
With a well-functioning outpatient service for this spe-
cial group of patients it cannot be ruled out that the
current intervention may have achieved other results.
Conclusion
The data indicate that PCC is a promising way to care
for patients with HNC in order to improve their func-
tion and well-being. The treatment period from between
the 4th and 10th week was the time period during which
the patients experienced the worst HRQoL fairly consist-
ently. After this period the patients gradually improved.
At all the follow-up points, the gPCC-G tended to feel
better than the CG and reported better QoL from the
18th week with almost no exception numerically, but
not always statistically significantly better. This result
implies that the gPCC concept was a health status-
improving substitute that at least partly compensated for
the negative effects of missing co-ordination and con-
tinuity of care.
Relevance to clinical practice
The findings in this study suggested that the PCC
concept should be included not only in clinical practice
but also in nursing education.
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